论文信息 - The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. - 字舞流文

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

J. Reynolds | A. Schwarer | J. Seymour | T. Hughes | S. Branford | A. Grigg | C. Arthur | D. Ross | R. Filshie | A. Mills | Ruth Columbus | Kerryn Loftus | T. Hughes